Extended-release trazodone (Oleptro) for depression.
The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro--Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been available for treatment of depression for many years, but is used mostly in low doses for its sedating effects.
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology*; D004244:Dizziness / Q000139:chemically induced; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D014196:Trazodone / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D014196:Trazodone